**ASX/Media Release**
**13 December 2016**

**ASX code: PIQ**

Proteomics International
LABORATORIES LTD

# SECONDARY TRADING NOTICE

Proteomics International Laboratories Ltd (ASX: PIQ) (the **Company**) confirms that further to the previous ASX announcement dated 2 December 2016, the Company has issued 6,000,000 fully paid ordinary shares (**Shares**) to new and existing sophisticated investors at an issue price of $0.24 per share to raise $1.44m (**Placement**) together with one for four attaching options (**Options**).

The Company has issued the Shares and Options using its 15% placement capacity.

**Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")**

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Shares and Options noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

(a) the Company issued the Shares and Options without disclosure to investors under Part 6D.2 of the Act;

(b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and

(c) as at the date of this Notice, there is no information:

(i) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and

(ii) that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:

a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or

b. the rights and liabilities attaching to the relevant Shares and Options.

**ENDS**

**For further information please contact:**

Karen Logan
Company Secretary
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

**About Proteomics International Laboratories (PILL)**

PILL (ASX: PIQ) is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

1. **Diagnostics:** Biomarkers of disease and personalised medicine - focus on diabetic kidney disease.
   By 2020 the biomarkers market is estimated to double in size to $45.6 billion, and the personalised medicine market is forecast to be worth over $149 billion.
2. **Analytical services:** Specialist contract research fee-for-service model – focus on biosimilars QC.
   The global biosimilars market is expected to reach $6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.
3. **Drug discovery:** Therapeutic peptide drug discovery - focus on painkillers and antibiotics.
   The global peptide therapeutics market is currently estimated to be worth $18 billion and is expected to increase at over 10% per year during 2016-2025.

In combination these areas offer, respectively, medium term products, near term cash flow, and blue sky potential by harnessing one complementary workflow centred on proteins.